Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis

Barts and the London NHS Trust (UK)0 个研究点目标入组 40 人开始时间: 2008年5月9日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Patients with a diagnosis of CF (positive sweat test or genotype testing)
•2. Patients aged greater than 16 years (post pubertal-stage IV Tanner), either sex
•3. Patients are pancreatic insufficient (i.e. with a positive faecal elastase test, and requiring pancreatic enzyme supplementation)
•4. No evidence of overt liver disease (not on ursodeoxycholic acid)

•1. Patients already taking vitamin K supplementation
•2. Patients with osteoporosis or osteopaenia and taking bisphosphonates
•3. Patients with abnormally low vitamin D levels (less than 30 µg)
•4. Patients on maintenance oral corticosteroids
•5. Patients who are considered to have very sedentary lifestyle or follow a rigorous exercise training programme
•6. Patients with overt liver disease
•7. Patients who do not consent to participate
•8. Patients with a life expectancy of less than 12 months
•9. Patients who are non-compliant with maintenance therapies

发起方

Barts and the London NHS Trust (UK)